In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Mediwound (MDWD), with a price target of $5.50. The company’s shares closed last Monday at $3.07, close to its 52-week low of $2.55.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -8.8% and a 31.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals, ThermoGenesis Holdings, and IntelGenx Technologies.
Mediwound has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.09 and a one-year low of $2.55. Currently, Mediwound has an average volume of 35.92K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture and commercialization of novel products to address needs in the fields of severe burn; chronic and other hard-to-heal wounds; and connective tissue disorders.
